Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

Myotonic dystrophy

Reviewed November 2006

What is myotonic dystrophy?

Myotonic dystrophy is an inherited disorder of the muscles and other body systems. It is the most common form of muscular dystrophy that begins in adulthood.

This disorder is characterized by progressive muscle wasting and weakness, particularly in the lower legs, hands, neck, and face. People with myotonic dystrophy often have prolonged muscle tensing (myotonia) and are not able to relax certain muscles after use. For example, a person may be unable to release a grip on a doorknob or handle.

Other signs and symptoms of myotonic dystrophy include clouding of the lens of the eye (cataracts) and abnormalities of the electrical signals that control the heartbeat (cardiac conduction defects). In affected men, hormonal changes may lead to balding and an inability to father a child (infertility). The features of this disorder usually develop during a person's twenties or thirties, although they can occur at any age. The severity of the condition varies widely among affected people, even among members of the same family.

The two types of myotonic dystrophy are designated type 1 and type 2. The clinical features of type 2 myotonic dystrophy tend to be milder than those of type 1, and the two types are caused by mutations in different genes.

A variation of type 1 myotonic dystrophy, called congenital myotonic dystrophy, can be noted at birth. The signs and symptoms include generalized weakness, weak muscle tone (hypotonia), club foot, breathing problems, developmental delays, and intellectual disability. In some cases, these medical problems are severe or life-threatening.

How common is myotonic dystrophy?

Myotonic dystrophy affects about 1 in 8,000 people worldwide. Type 1 is the most common form of the condition, accounting for about 98 percent of all cases. The remaining 2 percent of cases are myotonic dystrophy, type 2. The prevalence of the two types of myotonic dystrophy varies among different ethnic populations. For example, among people with German ancestry, type 2 may be as common as type 1.

What genes are related to myotonic dystrophy?

Myotonic dystrophy type 1 is caused by a mutation in the DMPK gene, while a mutation in the CNBP gene is responsible for the less common myotonic dystrophy type 2. The exact function of these genes is not known. The DMPK gene may play a role in communication within cells and appears to be important for the correct functioning of cells in the heart, brain, and muscles used for movement (skeletal muscles). The protein made by the CNBP gene is primarily found in the heart and in skeletal muscles, where it probably helps regulate the function of other genes.

Similar mutations in the DMPK and CNBP genes cause the two forms of myotonic dystrophy. In each case, a short segment of DNA is abnormally repeated many times, forming an unstable region in the gene. The mutated gene produces an altered version of messenger RNA, which is a molecular blueprint of the gene that is normally used for protein production. The abnormal messenger RNA forms clumps inside the cell that interfere with the production of many proteins. These changes prevent cells in muscles and other tissues from functioning normally, leading to the signs and symptoms of myotonic dystrophy.

How do people inherit myotonic dystrophy?

Both types of myotonic dystrophy are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one affected parent.

As myotonic dystrophy is passed from one generation to the next, the disorder generally begins earlier in life and signs and symptoms become more severe. This phenomenon is called anticipation. In type 1 myotonic dystrophy, anticipation is caused by an increase in the length of the unstable region in the DMPK gene. In type 2 myotonic dystrophy, a longer unstable region in the CNBP gene does not appear to influence the age of onset of the disorder. The cause of the anticipation observed in families with type 2 myotonic dystrophy is unknown.

Where can I find information about treatment for myotonic dystrophy?

You may find information on treatment or management of myotonic dystrophy or some of its symptoms in the links below, particularly the links for Gene Reviews, MedlinePlus Encyclopedia, Educational resources, and Patient support.

Where can I find additional information about myotonic dystrophy?

You may find the following resources about myotonic dystrophy helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

What other names do people use for myotonic dystrophy?

  • dystrophia myotonica
  • myotonia atrophica
  • myotonia dystrophica

See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What if I still have specific questions about myotonic dystrophy?

  • See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.
  • Ask the Genetic and Rare Diseases Information Center (http://rarediseases.info.nih.gov/GARD/).
  • Submit your question to Ask the Geneticist (http://www.askthegen.org/).

What glossary definitions help with understanding myotonic dystrophy?

anticipation ; autosomal ; autosomal dominant ; cardiac ; cataract ; cell ; club foot ; congenital ; developmental delay ; DNA ; gene ; hypotonia ; infertility ; messenger RNA ; muscle tone ; muscular dystrophy ; mutation ; myotonia ; population ; prevalence ; protein ; proximal ; RNA ; sign ; skeletal muscle ; symptom ; syndrome ; tissue ; wasting

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://ghr.nlm.nih.gov/glossary).

References
  • Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta. 2007 Feb;1772(2):195-204. Epub 2006 Jun 20. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16876389?dopt=Abstract)
  • Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord. 2005 Jan;15(1):5-16. Epub 2004 Nov 26. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15639115?dopt=Abstract)
  • Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003 Feb 25;60(4):657-64. (http://www.ncbi.nlm.nih.gov/pubmed/12601109?dopt=Abstract)
  • Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science. 2004 Jan 16;303(5656):383-7. Epub 2003 Dec 04. (http://www.ncbi.nlm.nih.gov/pubmed/14657503?dopt=Abstract)
  • Finsterer J. Myotonic dystrophy type 2. Eur J Neurol. 2002 Sep;9(5):441-7. Review. (http://www.ncbi.nlm.nih.gov/pubmed/12220374?dopt=Abstract)
  • Gene Review: Myotonic Dystrophy Type 1 (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=myotonic-d)
  • Gene Review: Myotonic Dystrophy Type 2 (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=myotonic-d2)
  • Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001 Aug 3;293(5531):864-7. (http://www.ncbi.nlm.nih.gov/pubmed/11486088?dopt=Abstract)
  • Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve. 2005 Jul;32(1):1-18. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15770660?dopt=Abstract)
  • Meola G, Moxley RT 3rd. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol. 2004 Oct;251(10):1173-82. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15503094?dopt=Abstract)
  • Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004 May;74(5):793-804. Epub 2004 Apr 02. (http://www.ncbi.nlm.nih.gov/pubmed/15065017?dopt=Abstract)
  • Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, Kress W, Schoser B, Moxley R. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord. 2006 Jun;16(6):403-13. Epub 2006 May 8. No abstract available. (http://www.ncbi.nlm.nih.gov/pubmed/16684600?dopt=Abstract)
  • Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol. 2007 Oct;20(5):572-6. Review. (http://www.ncbi.nlm.nih.gov/pubmed/17885447?dopt=Abstract)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: November 2006
Published: November 20, 2009